AGC completes Acquisition of Spanish manufacturer of synthetic active pharmaceutical ingredients Malgrat pharmaceutical Chemicals

Tokyo (ots/PRNewswire) – AGC, Inc. with its headquarters in Tokyo on 4 has. March the completion of the Acquisition of Malgrat Pharma Chemicals S. L. U. (hereinafter referred to as MPC) announced, a Spain-based manufacturer of synthetic active pharmaceutical ingredients. The transaction was already at 4. December 2018 have been announced. The acquisition of the relevant financial results will be reflected in the consolidated financial statements of AGC as of the first quarter of fiscal year 2019.

(Logo:
https://kyodonewsprwire.jp/prwfile/release/M000303/201902273656/_prw_
PI1fl_cNR5l3L0.png)

The acquisition of MPC enables AGC, now in Europe, intermediates for synthetic medicines (*1) to active ingredients to manufacture and process. AGC, which provides its pharmaceutical customers from Japan, with a proprietary fluorine technology and comprehensive In-house Drug Discovery Expertise, this can lead to an additional physical location. MPC works in a cGMP-compliant (*2) and can present as a production site of a long-standing Tradition with a strong record of success. The production lines of the company are designed for different requirements from the development phase up to market pharmaceuticals tires. AGC hopes to raise with this acquisition its presence in the European market, where a significant increase in demand, and its CDMO business (*3) for synthetic pharmaceuticals to customers around the world continue to expand.

In the framework of its „AGC plus“Management policy the AGC Group has declared the Life-Science business one of its strategic initiatives. By 2020, turnover of about 65 billion Yen to be achieved by 2025, sales of over 100 billion Yen. With the Acquisition of MPC, the AGC Group will win according to the already completed Acquisition of two biopharmaceutical CDMO companies, namely, Biomeva (2016) and CMC Biologics (2017), an additional outside Japan description production and sales base. The AGC Group will look after the completion of this latest acquisition also continues to be proactive in new ways and in their fields of business for synthetic materials, and Biopharmaceuticals, to invest, to pursue their self-declared aim to make a contribution for pharmaceutical companies and for the benefit of patients and the wider society as a whole.

Comments

(*1) Synthetic pharmaceuticals: pharmaceuticals that are manufactured by chemical synthesis

(*2) cGMP: standards for the manufacture and quality control of medicines and Quasi-medicines (which is the short form of cGMP for:
current Good Manufacturing Practice)

(*3) CDMO: Contract Development & Manufacturing Organization (a contract manufacturer and developer). What is meant is a company that leads the production as well as the development of production methods in the order of a third party.

Detailed information can be found at:

https://kyodonewsprwire.jp/attach/201902273656-O1-kipNxYZ1.pdf

Yuki Kitano
Corporate Communications & Investor Relations Division
AGC Inc.
Tel: +81-3-3218-5603
E-Mail: info-pr@agc.com